Want to see HK:2617 full AI Analyst Report?
2617 Stock Chart & Stats
HK$10.66
--
Market closed
HK$10.66
--
Day’s Range― - ―
52-Week RangeHK$9.01 - HK$246.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)5.86M
Market Cap
HK$3.42B
Enterprise ValueHK$3.65K
Total Cash (Recent Filing)HK$925.22M
Total Debt (Recent Filing)HK$5.61M
Price to Earnings (P/E)―
Beta3.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding312,687,680
10 Day Avg. Volume8,164,631
30 Day Avg. Volume5,858,137
Financial Highlights & Ratios
PEG Ratio-13.39
Price to Book (P/B)96.58
Price to Sales (P/S)0.00
P/FCF Ratio-158.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageVery low debt relative to equity limits refinancing and interest-rate exposure, giving the company greater financial flexibility while it develops its pipeline. This conservative financing structure reduces near-term solvency pressure compared with a heavily leveraged biotechnology business.
Proprietary Drug Development FocusA proprietary small-molecule research platform gives TransThera an internally controlled route from discovery through clinical development and potential commercialization. If candidates progress successfully, this model can support differentiated products and longer-term value creation beyond fee-based research activity.
Improving Free Cash Flow TrendAlthough cash flow remains materially negative, improvement in free cash flow over two consecutive years indicates some progress in the pace of cash consumption. Sustaining that trend could extend funding runway and reduce the urgency of external financing as development programs advance.
Bears Say
Pre-Revenue Operating ProfileThe absence of reported revenue in the two latest annual periods shows that the company has not yet established a commercial income base. This leaves future funding and operating performance dependent on clinical progress, regulatory milestones, and eventual product commercialization.
Persistent Large Net LossesLarge and persistent net losses indicate that research and development spending is not yet supported by operating earnings. Continued losses can erode equity and assets over time, constrain capital allocation, and increase the financial burden of bringing candidates through later development stages.
Sustained Cash BurnMaterially negative operating and free cash flow demonstrate that the business is consuming substantial cash each year. Because free cash flow closely tracks net losses, the company has limited non-cash support and may require external funding if the burn rate persists.
TransThera Sciences (Nanjing). Inc. News
2617 FAQ
What was TransThera Sciences (Nanjing). Inc.’s price range in the past 12 months?
TransThera Sciences (Nanjing). Inc. lowest stock price was HK$9.01 and its highest was HK$246.00 in the past 12 months.
What is TransThera Sciences (Nanjing). Inc.’s market cap?
TransThera Sciences (Nanjing). Inc.’s market cap is HK$3.42B.
When is TransThera Sciences (Nanjing). Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were TransThera Sciences (Nanjing). Inc.’s earnings last quarter?
Currently, no data Available
Is TransThera Sciences (Nanjing). Inc. overvalued?
According to Wall Street analysts TransThera Sciences (Nanjing). Inc.’s price is currently Overvalued.
Does TransThera Sciences (Nanjing). Inc. pay dividends?
TransThera Sciences (Nanjing). Inc. does not currently pay dividends.
What is TransThera Sciences (Nanjing). Inc.’s EPS estimate?
TransThera Sciences (Nanjing). Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TransThera Sciences (Nanjing). Inc. have?
TransThera Sciences (Nanjing). Inc. has 312,687,680 shares outstanding.
What happened to TransThera Sciences (Nanjing). Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TransThera Sciences (Nanjing). Inc.?
Currently, no hedge funds are holding shares in HK:2617
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TransThera Sciences (Nanjing). Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
50.32%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
TransThera Sciences (Nanjing). Inc.
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company provides Tinengotinib (TT-00420), a MTK inhibitor that is in clinical stage for the treatment of recurrent or refractory drug-resistant solid tumors. It also develops TT-00973, a kinase inhibitor for treating various cancers; TT-01488, a BTK inhibitor for the treatment of B-cell lymphoma; TT-01688, an oral S1P1 modulator for treating various inflammatory diseases; TT-00920, an oral PDE9 inhibitor used for treating central nervous system diseases; TT-01025, an oral irreversible VAP-1 inhibitor designed for the treatment of NASH; and TT-02332, a NLRP3 inhibitor for metabolic and inflammatory diseases. The company has a collaboration with Neurocrine Biosciences, Inc. to develop NLRP3 inhibitors for multiple disease. TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021. The company was incorporated in 2014 and is headquartered in Nanjing, China.
Technical Analysis
Genscript Biotech
―
Zai Lab Ltd
―
RemeGen Co. Ltd. Class H
―
Shanghai Junshi Biosciences Co., Ltd. Class H
―
Shanghai Henlius Biotech, Inc. Class H
―